30% off. Use code SUMMER30 at checkout for 30% off for 12 months on Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Foamix Pharmaceuticals Ltd (FOMX)

Track

Stock chart
Ticker: FOMX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Hadar Ilan
CFO & Country Manager
1 sale — total 120,375 USD
Planned sale 10 Sep 2019
Value US$2,652,329.05 | Price 192.61 | Shares 99,878
Planned sale 9 Sep 2019
Value US$4,139,044.76 | Price 88.17 | Shares 23,228
Sale 26 Aug 2019
Value US$23,050.23 | Price 3.27 | Shares 7,049
Planned sale 15 Jul 2019
Value US$1,866.48 | Price 2.31 | Shares 808
Sale 1 Jul 2019
Value US$1,501.65 | Price 2.35 | Shares 639
Sale 1 Jul 2019
Value US$2,234.85 | Price 2.35 | Shares 951
Sale 1 Jul 2019
Value US$7,884.25 | Price 2.35 | Shares 3,355
Planned sale 20 May 2019
Value US$27,666.00 | Price 2.61 | Shares 10,600
Sale 1 Apr 2019
Value US$6,360.00 | Price 3.75 | Shares 1,696
Sale 1 Apr 2019
Value US$9,446.25 | Price 3.75 | Shares 2,519
Sale 1 Apr 2019
Value US$19,110.00 | Price 3.75 | Shares 5,096
Buy 5 Mar 2019
Value US$50,534.40 | Price 3.76 | Shares 13,440
Sale 3 Dec 2018
Value US$275.40 | Price 4.05 | Shares 68
Buy 28 Nov 2018
Value US$47,372.60 | Price 3.88 | Shares 12,200
Buy 27 Nov 2018
Value US$195,800.00 | Price 3.92 | Shares 50,000
Buy 26 Nov 2018
Value US$194,600.00 | Price 3.89 | Shares 50,000
Sale 19 Nov 2018
Value US$19,640.40 | Price 3.90 | Shares 5,036
Sale 19 Nov 2018
Value US$13,162.50 | Price 3.90 | Shares 3,375
Sale 8 Nov 2018
Value US$9,443.96 | Price 4.58 | Shares 2,062
Sale 8 Nov 2018
Value US$3,128.14 | Price 4.58 | Shares 683
Sale 1 Oct 2018
Value US$3,491.81 | Price 5.81 | Shares 601
Sale 1 Oct 2018
Value US$825.02 | Price 5.81 | Shares 142
Sale 1 Oct 2018
Value US$1,359.54 | Price 5.81 | Shares 234
Sale 4 Sep 2018
Value US$379.89 | Price 5.67 | Shares 67
Sale 8 Aug 2018
Value US$46,791.84 | Price 5.68 | Shares 8,238
Sale 8 Aug 2018
Value US$15,421.20 | Price 5.68 | Shares 2,715
Sale 2 Jul 2018
Value US$3,070.20 | Price 5.10 | Shares 602
Sale 2 Jul 2018
Value US$724.20 | Price 5.10 | Shares 142
Sale 2 Jul 2018
Value US$1,193.40 | Price 5.10 | Shares 234
Sale 1 Jun 2018
Value US$352.42 | Price 5.26 | Shares 67
Sale 13 May 2018
Value US$31,368.60 | Price 5.09 | Shares 6,164
Sale 2 Apr 2018
Value US$1,188.72 | Price 5.08 | Shares 234
Sale 2 Apr 2018
Value US$721.36 | Price 5.08 | Shares 142
Sale 2 Apr 2018
Value US$3,058.16 | Price 5.08 | Shares 602
Sale 2 Mar 2018
Value US$5,016.38 | Price 6.14 | Shares 817
Sale 1 Mar 2018
Value US$392.70 | Price 5.95 | Shares 66
Planned sale 11 Jan 2018
Value US$31,658.50 | Price 6.33 | Shares 5,000
Planned sale 10 Jan 2018
Value US$30,227.00 | Price 6.05 | Shares 5,000
Planned sale 9 Jan 2018
Value US$30,520.00 | Price 6.10 | Shares 5,000
Planned sale 8 Jan 2018
Value US$30,850.00 | Price 6.17 | Shares 5,000
Planned sale 5 Jan 2018
Value US$32,881.50 | Price 6.58 | Shares 5,000
Planned sale 4 Jan 2018
Value US$33,411.00 | Price 6.68 | Shares 5,000
Planned sale 3 Jan 2018
Value US$31,310.50 | Price 6.26 | Shares 5,000
Planned sale 2 Jan 2018
Value US$30,902.50 | Price 6.18 | Shares 5,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-09-11 2019-09-10 PlS Planned sale
Hadar Ilan

CFO & Country Manager
99,878 -47.7%
192.61
US$2,652,329 		99,878 -47.7% 192.61 US$2,652,329
2019-09-11 2019-09-09 PlS Planned sale
Hadar Ilan

CFO & Country Manager
23,228 -30.6%
88.17
US$4,139,045 		23,228 -30.6% 88.17 US$4,139,045
2019-08-28 2019-08-26 S Sale KAZANCHYAN ANNA Non-Executive Director
87,035 +39.6%
227.47
US$1,132,986 		87,035 +39.6% 227.47 US$1,132,986
2019-07-17 2019-07-15 PlS Planned sale
KAZANCHYAN ANNA
808 -1.8%
2.31
US$1,866 		808 -1.8% 2.31 US$1,866
2019-07-03 2019-07-01 S Sale
Harsch Mutya

CLO and General Counsel
639 -1.2%
2.35
US$1,502 		639 -1.2% 2.35 US$1,502
2019-07-03 2019-07-01 S Sale
2.8
Stuart Iain

Chief Scientific Officer
951 -1.5%
2.35
US$2,235 		951 -1.5% 2.35 US$2,235
2019-07-03 2019-07-01 S Sale
3.2
Domzalski David

CEO

Executive Director
3,355 -1.6%
2.35
US$7,884 		3,355 -1.6% 2.35 US$7,884
2019-05-20 2019-05-20 PlS Planned sale
KAZANCHYAN ANNA
Non-Executive Director
10,600 -18.9%
2.61
US$27,666 		10,600 -18.9% 2.61 US$27,666
2019-04-03 2019-04-01 S Sale
2.8
Stuart Iain

Chief Scientific Officer
1,696 -2.6%
3.75
US$6,360 		1,696 -2.6% 3.75 US$6,360
2019-04-03 2019-04-01 S Sale
Harsch Mutya

CLO and General Counsel
2,519 -4.6%
3.75
US$9,446 		2,519 -4.6% 3.75 US$9,446
2019-04-03 2019-04-01 S Sale
3.2
Domzalski David

CEO

Executive Director
5,096 -2.3%
3.75
US$19,110 		5,096 -2.3% 3.75 US$19,110
2019-03-06 2019-03-05 B Purchase
Wiley Matthew T.

Chief Commercial Officer
13,440 +26.9%
3.76
US$50,534 		13,440 +26.9% 3.76 US$50,534
2018-12-06 2018-12-03 S Sale Domzalski David

CEO

Executive Director
68 -0.0%
4.05
US$275 		68 -0.0% 4.05 US$275
2018-12-06 2018-11-28 B Purchase Schwartz Aharon Non-Executive Director
12,200 +12.2%
3.88
US$47,373 		12,200 +12.2% 3.88 US$47,373
2018-12-06 2018-11-27 B Purchase Schwartz Aharon Non-Executive Director
50,000 +100.0%
3.92
US$195,800 		50,000 +100.0% 3.92 US$195,800
2018-12-06 2018-11-26 B Purchase Schwartz Aharon Non-Executive Director
50,000 +inf%
3.89
US$194,600 		50,000 +inf% 3.89 US$194,600
2018-11-20 2018-11-19 S Sale Domzalski David

CEO

Executive Director
5,036 -3.3%
3.90
US$19,640 		5,036 -3.3% 3.90 US$19,640
2018-11-20 2018-11-19 S Sale Howard Alvin D

VP Regulatory

Officer
3,375 -8.1%
3.90
US$13,162 		3,375 -8.1% 3.90 US$13,162
2018-11-13 2018-11-08 S Sale Domzalski David

CEO

Executive Director
2,062 -1.3%
4.58
US$9,444 		2,062 -1.3% 4.58 US$9,444
2018-11-13 2018-11-08 S Sale Stuart Iain

SVP R&D

Officer
683 -2.0%
4.58
US$3,128 		683 -2.0% 4.58 US$3,128
2018-10-02 2018-10-01 S Sale Domzalski David

CEO

Executive Director
601 -0.4%
5.81
US$3,492 		601 -0.4% 5.81 US$3,492
2018-10-02 2018-10-01 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.81
US$825 		142 -1.1% 5.81 US$825
2018-10-02 2018-10-01 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.81
US$1,360 		234 -0.6% 5.81 US$1,360
2018-09-06 2018-09-04 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.67
US$380 		67 -0.0% 5.67 US$380
2018-08-09 2018-08-08 S Sale Domzalski David

CEO

Executive Director
8,238 -5.1%
5.68
US$46,792 		8,238 -5.1% 5.68 US$46,792
2018-08-09 2018-08-08 S Sale Stuart Iain

SVP R&D

Officer
2,715 -7.3%
5.68
US$15,421 		2,715 -7.3% 5.68 US$15,421
2018-07-03 2018-07-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.10
US$3,070 		602 -0.4% 5.10 US$3,070
2018-07-03 2018-07-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.10
US$724 		142 -1.1% 5.10 US$724
2018-07-03 2018-07-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.10
US$1,193 		234 -0.6% 5.10 US$1,193
2018-06-04 2018-06-01 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.26
US$352 		67 -0.0% 5.26 US$352
2018-05-31 2018-05-13 S Sale Hirsch Stanley Non-Executive Director
6,164 -48.6%
5.09
US$31,369 		6,164 -48.6% 5.09 US$31,369
2018-04-04 2018-04-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.08
US$1,189 		234 -0.6% 5.08 US$1,189
2018-04-04 2018-04-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.08
US$721 		142 -1.1% 5.08 US$721
2018-04-04 2018-04-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.08
US$3,058 		602 -0.4% 5.08 US$3,058
2018-03-06 2018-03-02 S Sale Elliott Russell P.

VP Drug Development
817 -6.0%
6.14
US$5,016 		817 -6.0% 6.14 US$5,016
2018-03-05 2018-03-01 S Sale Domzalski David

CEO

Executive Director
66 -0.0%
5.95
US$393 		66 -0.0% 5.95 US$393
2018-01-18 2018-01-11 PlS Planned sale Eini Meir
5,000 -0.2%
6.33
US$31,658 		5,000 -0.2% 6.33 US$31,658
2018-01-18 2018-01-10 PlS Planned sale Eini Meir
5,000 -0.2%
6.05
US$30,227 		5,000 -0.2% 6.05 US$30,227
2018-01-18 2018-01-09 PlS Planned sale Eini Meir
5,000 -0.2%
6.10
US$30,520 		5,000 -0.2% 6.10 US$30,520
2018-01-18 2018-01-08 PlS Planned sale Eini Meir
5,000 -0.2%
6.17
US$30,850 		5,000 -0.2% 6.17 US$30,850
2018-01-18 2018-01-05 PlS Planned sale Eini Meir
5,000 -0.2%
6.58
US$32,882 		5,000 -0.2% 6.58 US$32,882
2018-01-18 2018-01-04 PlS Planned sale Eini Meir
5,000 -0.2%
6.68
US$33,411 		5,000 -0.2% 6.68 US$33,411
2018-01-18 2018-01-03 PlS Planned sale Eini Meir
5,000 -0.2%
6.26
US$31,310 		5,000 -0.2% 6.26 US$31,310
2018-01-18 2018-01-02 PlS Planned sale Eini Meir
5,000 -0.2%
6.18
US$30,902 		5,000 -0.2% 6.18 US$30,902
Explore more

More insider trading research around Foamix Pharmaceuticals Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America